Background: DNA methylation (DNAm) age acceleration (AgeAccel) has been shown to be predictive of all-cause mortality but it is unclear what functional aspect/s of ageing it captures. We examine associations between four measures of AgeAccel in adults aged 45-87 years and physical and cognitive performance and their age-related decline.
INTRODUCTION
The worldwide demographic shift towards an ageing population is accompanied by an increase in life expectancy; however the quality of these extra years remains unclear [1] [2] [3] .
Ageing is a dynamic and complex process characterised by an array of cellular and molecular changes which accumulate over the life course to manifest as impaired function and an increased susceptibility to multiple chronic diseases and death 4 . The heterogeneity in agerelated disease and functional capability cannot be explained by chronological age (CA) alone 5 . Therefore, a measure of biological age that can capture the ageing process beyond what is represented by CA may identify people at risk of functional impairment, providing an insight into their health-related quality of life.
Numerous biomarkers of ageing have been proposed including epigenetic biomarkers based on DNA methylation (DNAm) [6] [7] [8] [9] [10] . Over recent years, a number of DNAm-based biomarkers of ageing have been developed 8, [11] [12] [13] [14] [15] . The first generation of these biomarkers were developed to predict CA and include the blood-based Hannum and the multi-tissue Horvath algorithms which show a high correlation with, and small deviation from CA 12, 13 . More recently, second generation DNAm-based biomarkers of ageing have been developed with the specific aim of identifying CpGs that capture lifespan and healthspan in addition to those displaying changes with chronological time. One of these, the DNAm-based Phenotypic Age (PhenoAge), identified CpGs that predict a composite measure of mortality-related clinical physiological measures and CA 14 . Another began by generating surrogate DNAm biomarkers of age-related physiological measures and smoking pack years then regressed time-to-death on these DNAm surrogates and CA to produce the DNAm GrimAge 15 .
Having a higher DNAm age independent of CA (denoted age acceleration, AgeAccel), in all of these biomarkers has been shown to be associated with an increased risk of premature all- showing stronger associations than AgeAccelHannum or AgeAccelHorvath [14] [15] [16] [17] [18] [19] [20] [21] . However, it is unclear what functional aspects of ageing these DNAm-based biomarkers of ageing capture, and whether they can act as a proxy for an individual's health beyond mortality and disease.
The maintenance of physical and cognitive performance are vital components of healthy ageing and poorer performance has been associated with higher subsequent mortality rates 22, 23 . Therefore examining associations between DNAm-based biomarkers of ageing and age-related measures of performance and their decline may provide insight into the validity of these as biomarkers of healthy ageing. Previous evidence from a small number of studies has been inconsistent and focused on the first generation of DNAm-based biomarkers [24] [25] [26] [27] [28] . Two studies examining AgeAccelHannum and AgeAccelHorvath and change in physical and cognitive performance were either sex-specific, had small sample sizes and/or did not examine a wide range of performance measures 25, 27 . Another study examining a range of performance measures among 70 year olds observed cross-sectional but not longitudinal associations between AgeAccelHorvath, AgeAccelHannum and poorer grip strength, lung function and cognitive performance 24 . 
METHODS

Participants
Participants from three cohorts (NSHD, NCDS and TwinsUK) have all been described in detail previously [29] [30] [31] [32] . Eligible participants had information on DNAm and at least one measure of physical and cognitive performance at the same or a later time point. In NSHD, DNAm and physical and cognitive performance were measured when participants were 53(n=1375) and 60-64 years(n=672). Of the participants with DNAm at 53 years, 973 also had physical and cognitive performance measured at 69 years. Participants from NCDS had DNAm and lung function measured at 45 years and cognitive performance measured at 50 years(n=240). For TwinsUK, 120 monozygotic female twins (60 twin pairs) had DNAm profiled when aged 46-87 years and markers of physical performance measured up to seven years before or after. The mean absolute differences between when DNAm was measured and when grip strength, chair rise speed and lung function was measured was 3, 0.7 and 0.4 years respectively.
DNAm-based biomarkers of ageing
Blood samples for each cohort were taken as previously described 29, 32, 33 . DNAm was measured at >850 000 CpG sites in each cohort using Infinium MethylationEPIC BeadChips and processed using the ENmix package 34 in R 35 to obtain methylation beta-values. Quality control procedures were applied (supplementary material). We estimated four DNAm-based biomarkers of ageing in each cohort: DNAm AgeHannum, DNAm AgeHorvath, DNAm PhenoAge, and DNAm GrimAge [12] [13] [14] [15] . We calculated these four DNAm-based biomarkers of ageing using available software (https://labs.genetics.ucla.edu/horvath/dnamage/) with the normalisation option and advanced analysis for blood samples. Following the notation of previous publications, CA-independent DNAm-based biomarkers were calculated within the T-lymphocytes, CD4+ T-lymphocytes, B cells, natural killer cells, monocytes and granulocytes) were also calculated within this software.
Ageing outcomes
We selected three measures of physical (grip strength, chair rise speed and lung function [forced expiratory volume in one second, FEV1]) and two measures of cognitive performance (episodic memory and mental speed); each of which were available in NSHD and at least one other study. All these performance measures were available in NSHD. Cognitive performance and FEV1 were measured in NCDS, while TwinsUK collected the three physical performance measures. Details of how each of these measures were assessed is outlined in supplementary material.
Covariates
We selected the covariates a priori based on previous studies 24, 27 to include in sensitivity analyses: body mass index(BMI), height(m), smoking status, and socioeconomic position indicated by either occupational social class or income. We used covariates measured at the same time as the blood samples. For longitudinal analyses in NSHD, we included timevarying BMI and smoking status measured at 53, 60-64y and 69 years. Details of how each of these covariates were measured is outlined in supplementary material
Statistical analyses
All analyses were conducted using the four AgeAccel biomarkers: further mention of AgeAccel refers to all biomarkers unless specified. First, we examined associations between AgeAccel and each performance measure within each cohort. Linear regression models were used in NSHD and NCDS and linear mixed models in TwinsUK, including a random effect for twin pair to account for familial effects.
We adjusted for sex (in NSHD and NCDS) and CA (in months). We tested for interaction between AgeAccel and sex by including a multiplicative term. We tested for the presence of non-linear associations by including a quadratic term of AgeAccel in regression models.
Results from within-cohort analyses were then combined using random effects meta-analyses.
AgeAccel was available in NSHD at two different time points; 53 and 60-64 years. Therefore, we subsequently conducted the primary meta-analyses using data collected at 53 years with a sensitivity analysis including data from 60-64 years.
Second, in NSHD we used linear mixed models with random intercepts and slopes to examine if physical and cognitive performance measures between 53 and 69 years were associated with AgeAccel at 53 years. We included AgeAccel, sex, and CA (in months) at the 53 year measurement as fixed effects. We then tested interactions between time and AgeAccel at 53 years using a log-likelihood ratio test to determine if it was associated with rate of decline in the performance measures.
Third, in NSHD we examined if change in AgeAccel between 53 and 60-64 years was associated with change in performance between 53 and 60-64 years. Linear regression models with Δperformance (i.e. performance at 60-64 years-performance at 53 years) as the outcome and ΔAgeAccel as the exposure were used. Models were adjusted for performance at 53 years.
Sensitivity analyses were performed repeating each set of analysis with adjustment for BMI, height, smoking status, and social class or income. Since the blood-based AgeAccel measures are correlated with cell composition 14, 15, 17 and cell-composition changes with age, we Table 1 outlines characteristics of the study participants. The correlation coefficients between the different AgeAccel measures were similar within each study. AgeAccelHannum, AgeAccelHorvath and AgeAccelPheno were moderately correlated (ranging from r=0.33 for AgeAccelHannum and AgeAccelPheno in TwinsUK to r=0.58 for AgeAccelHannum and AgeAccelPheno in NCDS). AgeAccelGrim was also moderately correlated with AgeAccelPheno within each study (ranging from r=0.36 in NSHD 60-64 years to r=0.39 to r=0.40 in all other studies). However, AgeAccelGrim had weak correlations with AgeAccelHannum within each study (r=≤0.25) and no correlation with AgeAccelHorvath (r=≤0.06 in NSHD at 60-64 years, NCDS and TwinsUK r=0.13 in NSHD at 53 years).
RESULTS
(Table one here)
Associations between AgeAccel and physical and cognitive performance across the three cohorts
We found no evidence for associations between AgeAccelHannum or AgeAccelHorvath and physical or cognitive performance in meta-analyses (figures 1-5, supplementary tables 1-2).
There was evidence of a non-linear association (plinearity=0.04) and sex interaction (pinteraction=0.01) between AgeAccelHorvath and FEV1. When stratified by sex, effect sizes for the association between AgeAccelHorvath and FEV1 were in opposite directions. In women, higher AgeAccelHorvath was associated with lower FEV1, but in men with better FEV1 (supplementary table 2). Higher AgeAccelPheno was associated with weaker grip strength, lower FEV1 and slower mental speed (Supplementary table 3 and figures 1 -5) . Higher AgeAccelGrim was associated with lower FEV1, poorer episodic memory and slower mental speed (Supplementary table 4 and figures 1-5). There was no evidence for a sex interaction with AgeAccelPheno or AgeAccelGrim and any of the performance measures. Estimates for the association between AgeAccelGrim and physical and cognitive performance tended to be stronger than 
Associations between change in AgeAccel and change in physical and cognitive performance between 53 and 60-64 years in NSHD
In NSHD 482 participants had AgeAccel information at both 53 and 60-64 years. There was some evidence for an association between greater change in ΔAgeAccelPheno and change in chair rise speed ( ( Table 3 here)
DISCUSSION
We found evidence of relationships between the second generation of DNAm-based biomarkers of ageing (AgeAccelPheno and AgeAccelGrim) and physical and cognitive performance among participants aged 45 to 87 years that were not observed for the first generation biomarkers (AgeAccelHannum and AgeAccelHorvath). In addition, associations between AgeAccelGrim and subsequent decline in performance was also observed.
Identifying a reliable and valid biomarker of ageing has the potential to progress the understanding of, and slow the rate of ageing 36 . While AgeAccel has been heralded as a promising ageing biomarker 6 , evidence to date has focused on the first generation of DNAmbased biomarkers and has been sparse and inconsistent. Findings from a previous crosssectional study examining associations between AgeAccelHannum or AgeAccelHorvath in 486 MZ twins aged 55 to 79 years and general cognitive function were in line with our null results 25 . In contrast to our findings, a separate study of middle-aged female MZ twins (n=24 One previous study examined the association between AgeAccelHorvath and physical performance using data from a smaller sub-sample of NSHD women 27 . In this study no associations between AgeAccelHorvath measured using blood samples at 53 years and grip strength or chair rise time at 53 or 60-64 years were observed; unlike results from our study, AgeAccelHorvath at baseline (53 years) was modestly associated with a greater decline in BeadChips while our study used Infinium MethylationEPIC BeadChips. In addition, half of these women were selected because they developed breast cancer and thus findings in this subsample may not be representative of all women.
The second-generation DNAm-based biomarkers of ageing have been developed more recently with the specific aim of acting as a biomarker for healthspan (AgeAccelPheno) and lifespan (AgeAccelGrim). While AgeAccelPheno and AgeAccelGrim have been associated with age-related disease, and mortality 14, 15 , to our knowledge, no study to date has examined their associations with physical of cognitive performance. Although all correlations were in the expected direction, it is unclear why we observed associations between AgeAccelPheno and AgeAccelGrim for some but not all age-related performance measures. Over 95 per cent of the participants included in our meta-analyses are aged 65 or younger. It is possible that the variation in both age-related performance and AgeAccel in this age group is small, however decline in age-related performance has been shown to be evident prior to 65 years [37] [38] [39] [40] [41] .
Furthermore, older participants tend to have a lower AgeAccel than younger participants, indicating the presence of survivor bias 42, 43 , which would be less evident in our younger sample. In sensitivity analysis for our meta-analysis, including data from NSHD participants at 60-64 years rather than 53 years, weakened the associations between AgeAccelPheno and performance measures because cross-sectional associations were weaker at the older age in NSHD.
Both AgeAccelPheno and AgeAccelGrim, as well as being associated cross-sectionally with performance measures were also associated with decline in FEV1 over a 16 year period. Lung function has been shown to decline in NSHD from as early as 43 years, 44 which might explain why we observe such a relationship in FEV1 but not other performance measures in our The second generation healthspan and lifespan biomarkers use differences in physiological status among individuals of the same CA to construct the score, unlike the first generation which use CA only. In line with findings for age-related disease 15 , we observed the strongest associations for age-related performance for AgeAccelGrim. DNAm AgeHannum is based on 71 CpGs while DNAm AgeHorvath with 353, DNAm PhenoAge with 513 CpGs, and DNAm GrimAge with 1,030 CpGs. Of the 513 CpGs for DNAm PhenoAge, 41 overlapped with DNAm AgeHorvath and with 6 DNAm AgeHannum. Furthermore, DNAm AgeHorvath was the only one of the biomarkers that was based on multiple-tissues, with the others using whole blood. Since both blood cell composition and DNAm changes with age 17, 45 , the blood-based DNAm-based biomarkers of age also reflect age-related changes in cell-type composition 14, 15 .
A previous study found that measures of AgeAccelHorvath and AgeAccelHannum that incorporate blood cell counts give stronger associations with all-cause mortality compared with measures independent of blood cell counts 17 . Adjusting for cell composition in our study generally weakened associations, but did not affect the overall conclusions except for associations between AgeAccelHannum and performance in NSHD. In line with previous findings that AgeAccelHannum measures that incorporate blood cell counts outperform measures that exclude them for mortality prediction, our observed associations were considerably attenuated.
To our knowledge, this is the largest study of AgeAccel and physical and cognitive performance to date and the only one that has included the second generation of DNAm-based biomarkers of healthspan and lifespan. The main strengths of our study were the inclusion of Although participants across the three cohorts are generally representative of the white British population [29] [30] [31] [32] , selection bias for this specific cross-cohort study may have influenced the observed associations. Participants from these cohorts were selected if they had information on DNAm, outcomes of interest and a range of other health and age-related variables. If having a lower AgeAccel and higher age-related performance was associated with participation, this could have introduced collider bias where estimates may be positively biased 46 . Finally, the performance measures were assessed slightly differently between the cohorts potentially introducing some heterogeneity, although there was little variation in observed effect sizes between the cohorts in most cases. For the meta-analyses, all associations in NSHD were cross-sectional but in NCDS cognitive performance were measured five years after DNAm age and performance was measured up to seven years before or after DNAm age in TwinsUK. It is possible that physical and cognitive performance changed during this period introducing some error in the observed effect sizes. In conclusion, our study found evidence to support the second generation of DNAm-based biomarkers of healthspan and lifespan as a proxy for age-related physical or cognitive performance in midto early old age, particularly for lung function. However, these findings should be replicated 
